A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus
The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dos...
Saved in:
| Published in | eNeurologicalSci Vol. 24; p. 100351 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier B.V
01.09.2021
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2405-6502 2405-6502 |
| DOI | 10.1016/j.ensci.2021.100351 |
Cover
| Abstract | The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective.
•We described a case of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS).•Treatment with low-dose cilostazol and lomerizine hydrochloride could therapeutic for RCVS with APS.•These treatments may alleviate the endothelin-1-related cerebral vascular dysfunction in RCVS/APS. |
|---|---|
| AbstractList | The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective.
•
We described a case of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS).
•
Treatment with low-dose cilostazol and lomerizine hydrochloride could therapeutic for RCVS with APS.
•
These treatments may alleviate the endothelin-1-related cerebral vascular dysfunction in RCVS/APS. The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective.The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective. The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective. The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective. •We described a case of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS).•Treatment with low-dose cilostazol and lomerizine hydrochloride could therapeutic for RCVS with APS.•These treatments may alleviate the endothelin-1-related cerebral vascular dysfunction in RCVS/APS. |
| ArticleNumber | 100351 |
| Author | Emoto, Noriaki Mimura, Naoya Takahashi, Ryosuke Maki, Takakuni Shima, Atsushi Yamashita, Hirofumi Yoshifuji, Hajime |
| Author_xml | – sequence: 1 givenname: Atsushi surname: Shima fullname: Shima, Atsushi organization: Department of Neurology, Kyoto University Graduate School of Medicine, Japan – sequence: 2 givenname: Takakuni surname: Maki fullname: Maki, Takakuni email: harutoma@kuhp.kyoto-u.ac.jp organization: Department of Neurology, Kyoto University Graduate School of Medicine, Japan – sequence: 3 givenname: Naoya surname: Mimura fullname: Mimura, Naoya organization: Department of Neurology, Kyoto University Graduate School of Medicine, Japan – sequence: 4 givenname: Hirofumi surname: Yamashita fullname: Yamashita, Hirofumi organization: Department of Neurology, Kyoto University Graduate School of Medicine, Japan – sequence: 5 givenname: Noriaki surname: Emoto fullname: Emoto, Noriaki organization: Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Japan – sequence: 6 givenname: Hajime surname: Yoshifuji fullname: Yoshifuji, Hajime organization: Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan – sequence: 7 givenname: Ryosuke surname: Takahashi fullname: Takahashi, Ryosuke organization: Department of Neurology, Kyoto University Graduate School of Medicine, Japan |
| BookMark | eNqFUstuFDEQHKEgEkK-gIuPXHbxezwHkKKIR6RIXOBseeyerFcz9mJ7Fu0_5KPx7kQo4QAHy3Z1VdnqrtfNWYgBmuYtwWuCiXy_XUPI1q8ppqQimAnyormgHIuVFJiePTmfN1c5bzHGREgqCX3VnDNOheKEXTQP18iaDCgOKMEeUvb9CMhCgj6ZEe1NjjaGXJK3xceA8iG4FCdAJteKNwUc-uXLBplQ_Gq3ibmu0e-8OyF9dIcnmuDqJReYvEXjvJszgnQoG5hMiXnOb5qXgxkzXD3ul82Pz5--33xd3X37cntzfbeygrZk5aQSSjnSAe65EsKCVFQ5OQxgielI38oOiDSCK0aJ7IaOc6ta7oYWd8o6dtncLr4umq3eJT-ZdNDReH0CYrrXJhVvR9CSi4ELKYWxkreUGuVUB6wTihnFYKheHxev3dxP4CyEUhv3zPR5JfiNvo97rahgHVPV4N2jQYo_Z8hFTz5bGEcTIM5ZUyGIaJUiolLZQrUp5pxg-PMMwfoYC73Vp1joYyz0Eouq6v5SWV_McZr1P378j_bDooU6jr2HpCsDggXnE9hS--X_qf8NAfbYsQ |
| CitedBy_id | crossref_primary_10_1111_head_14501 crossref_primary_10_3892_br_2022_1560 crossref_primary_10_1177_19714009241247469 crossref_primary_10_3389_fneur_2024_1420201 crossref_primary_10_3390_brainsci12010091 crossref_primary_10_3995_jstroke_11045 crossref_primary_10_1002_brb3_3417 crossref_primary_10_1186_s41983_023_00607_9 crossref_primary_10_1007_s13760_023_02324_9 crossref_primary_10_3390_jcm13195930 |
| Cites_doi | 10.5692/clinicalneurol.53.283 10.1212/WNL.0000000000006917 10.1016/S1474-4422(12)70135-7 10.7326/0003-4819-146-1-200701020-00007 10.1371/journal.pone.0044476 10.1007/s10067-013-2434-9 10.1111/j.1538-7836.2006.01753.x 10.1177/0961203319845485 10.1002/1529-0131(199805)41:5<800::AID-ART5>3.0.CO;2-J 10.1016/S1474-4422(10)70198-8 10.1046/j.1440-1681.1999.03154.x |
| ContentType | Journal Article |
| Copyright | 2021 The Authors 2021 The Authors. 2021 The Authors 2021 |
| Copyright_xml | – notice: 2021 The Authors – notice: 2021 The Authors. – notice: 2021 The Authors 2021 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.ensci.2021.100351 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals (WRLC) url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2405-6502 |
| ExternalDocumentID | oai_doaj_org_article_645f45665ac64722a8d89e39583a83ef PMC8253938 10_1016_j_ensci_2021_100351 S2405650221000435 |
| GroupedDBID | 0R~ 0SF 457 6I. AACTN AAEDW AAFTH AALRI AAXUO ABMAC ACGFS ADBBV ADEZE AEXQZ AFTJW AGHFR AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS EJD FDB GROUPED_DOAJ HYE IPNFZ KQ8 M~E NCXOZ O9- OK1 RIG ROL RPM SSZ AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKRWK AKYEP APXCP CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c5271-d68588d19e0b4855ce6828d6ffec1a91b769e16a54832169f944c874df7098cd3 |
| IEDL.DBID | DOA |
| ISSN | 2405-6502 |
| IngestDate | Wed Aug 27 01:25:38 EDT 2025 Tue Sep 30 16:40:15 EDT 2025 Wed Oct 01 14:24:08 EDT 2025 Tue Jul 01 00:46:51 EDT 2025 Thu Apr 24 22:51:54 EDT 2025 Fri Feb 23 02:42:47 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Lomerizine Cilostazol Reversible cerebral vasoconstriction syndrome Anti-phospholipid antibody syndrome Endothelin-1 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5271-d68588d19e0b4855ce6828d6ffec1a91b769e16a54832169f944c874df7098cd3 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://doaj.org/article/645f45665ac64722a8d89e39583a83ef |
| PMID | 34258413 |
| PQID | 2551578815 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_645f45665ac64722a8d89e39583a83ef pubmedcentral_primary_oai_pubmedcentral_nih_gov_8253938 proquest_miscellaneous_2551578815 crossref_primary_10_1016_j_ensci_2021_100351 crossref_citationtrail_10_1016_j_ensci_2021_100351 elsevier_sciencedirect_doi_10_1016_j_ensci_2021_100351 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-01 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | eNeurologicalSci |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Shinohara, Katayama, Uchiyama, Yamaguchi, Handa, Matsuoka (bb0050) 2010; 9 Miyakis, Lockshin, Atsumi, Branch, Brey, Cervera (bb0025) 2006; 4 Uenaka, Hamaguchi, Sekiguchi, Kowa, Kanda, Toda (bb0010) 2013; 53 Calabrese, Dodick, Schwedt, Singhal (bb0055) 2007; 146 Petri, Orbai, Alarcon, Gordon, Merrill, Fortin (bb0030) 2011; 63 Rocha, Topcuoglu, Silva, Singhal (bb0035) 2019; 92 Hara, Shimazawa, Sasaoka, Yamada, Iwakura, Sakai (bb0060) 1999; 26 Kawanabe, Takahashi, Jin, Abdul-Majeed, Nauli, Sari (bb0040) 2012; 7 Ducros (bb0045) 2012; 11 Gupta, Zivadinov, Ramasamy, Ambrus (bb0005) 2014; 33 Chung, Lee, Heo, Ra, Hong, Yang (bb0015) 2019; 28 Atsumi, Khamashta, Haworth, Brooks, Amengual, Ichikawa (bb0020) 1998; 41 Gupta (10.1016/j.ensci.2021.100351_bb0005) 2014; 33 Shinohara (10.1016/j.ensci.2021.100351_bb0050) 2010; 9 Petri (10.1016/j.ensci.2021.100351_bb0030) 2011; 63 Miyakis (10.1016/j.ensci.2021.100351_bb0025) 2006; 4 Calabrese (10.1016/j.ensci.2021.100351_bb0055) 2007; 146 Rocha (10.1016/j.ensci.2021.100351_bb0035) 2019; 92 Ducros (10.1016/j.ensci.2021.100351_bb0045) 2012; 11 Chung (10.1016/j.ensci.2021.100351_bb0015) 2019; 28 Atsumi (10.1016/j.ensci.2021.100351_bb0020) 1998; 41 Uenaka (10.1016/j.ensci.2021.100351_bb0010) 2013; 53 Kawanabe (10.1016/j.ensci.2021.100351_bb0040) 2012; 7 Hara (10.1016/j.ensci.2021.100351_bb0060) 1999; 26 |
| References_xml | – volume: 53 start-page: 283 year: 2013 end-page: 286 ident: bb0010 article-title: Reversible cerebral vasoconstriction syndrome in a stroke patient with systemic lupus erythematosus and antiphospholipid antibody publication-title: Rinsho Shinkeigaku – volume: 11 start-page: 906 year: 2012 end-page: 917 ident: bb0045 article-title: Reversible cerebral vasoconstriction syndrome publication-title: Lancet Neurol. – volume: 7 year: 2012 ident: bb0040 article-title: Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation publication-title: PLoS One – volume: 4 start-page: 295 year: 2006 end-page: 306 ident: bb0025 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J. Thromb. Haemost. – volume: 41 start-page: 800 year: 1998 end-page: 807 ident: bb0020 article-title: Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1 publication-title: Arthritis Rheum. – volume: 92 year: 2019 ident: bb0035 article-title: RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome publication-title: Neurology. – volume: 63 year: 2011 ident: bb0030 article-title: Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus publication-title: Arthritis Rheum-Us – volume: 28 start-page: 898 year: 2019 end-page: 902 ident: bb0015 article-title: A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasoconstriction syndrome publication-title: Lupus. – volume: 9 start-page: 959 year: 2010 end-page: 968 ident: bb0050 article-title: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial publication-title: Lancet Neurol. – volume: 146 start-page: 34 year: 2007 end-page: 44 ident: bb0055 article-title: Narrative review: reversible cerebral vasoconstriction syndromes publication-title: Ann. Intern. Med. – volume: 33 start-page: 1829 year: 2014 end-page: 1833 ident: bb0005 article-title: Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature publication-title: Clin. Rheumatol. – volume: 26 start-page: 870 year: 1999 end-page: 876 ident: bb0060 article-title: Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs publication-title: Clin. Exp. Pharmacol. Physiol. – volume: 53 start-page: 283 year: 2013 ident: 10.1016/j.ensci.2021.100351_bb0010 article-title: Reversible cerebral vasoconstriction syndrome in a stroke patient with systemic lupus erythematosus and antiphospholipid antibody publication-title: Rinsho Shinkeigaku doi: 10.5692/clinicalneurol.53.283 – volume: 92 year: 2019 ident: 10.1016/j.ensci.2021.100351_bb0035 article-title: RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome publication-title: Neurology. doi: 10.1212/WNL.0000000000006917 – volume: 11 start-page: 906 year: 2012 ident: 10.1016/j.ensci.2021.100351_bb0045 article-title: Reversible cerebral vasoconstriction syndrome publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(12)70135-7 – volume: 63 year: 2011 ident: 10.1016/j.ensci.2021.100351_bb0030 article-title: Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus publication-title: Arthritis Rheum-Us – volume: 146 start-page: 34 year: 2007 ident: 10.1016/j.ensci.2021.100351_bb0055 article-title: Narrative review: reversible cerebral vasoconstriction syndromes publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-146-1-200701020-00007 – volume: 7 year: 2012 ident: 10.1016/j.ensci.2021.100351_bb0040 article-title: Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation publication-title: PLoS One doi: 10.1371/journal.pone.0044476 – volume: 33 start-page: 1829 year: 2014 ident: 10.1016/j.ensci.2021.100351_bb0005 article-title: Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature publication-title: Clin. Rheumatol. doi: 10.1007/s10067-013-2434-9 – volume: 4 start-page: 295 year: 2006 ident: 10.1016/j.ensci.2021.100351_bb0025 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2006.01753.x – volume: 28 start-page: 898 year: 2019 ident: 10.1016/j.ensci.2021.100351_bb0015 article-title: A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasoconstriction syndrome publication-title: Lupus. doi: 10.1177/0961203319845485 – volume: 41 start-page: 800 year: 1998 ident: 10.1016/j.ensci.2021.100351_bb0020 article-title: Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1 publication-title: Arthritis Rheum. doi: 10.1002/1529-0131(199805)41:5<800::AID-ART5>3.0.CO;2-J – volume: 9 start-page: 959 year: 2010 ident: 10.1016/j.ensci.2021.100351_bb0050 article-title: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(10)70198-8 – volume: 26 start-page: 870 year: 1999 ident: 10.1016/j.ensci.2021.100351_bb0060 article-title: Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs publication-title: Clin. Exp. Pharmacol. Physiol. doi: 10.1046/j.1440-1681.1999.03154.x |
| SSID | ssj0001562612 |
| Score | 2.2027085 |
| Snippet | The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS)... |
| SourceID | doaj pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 100351 |
| SubjectTerms | Anti-phospholipid antibody syndrome Case Report Cilostazol Endothelin-1 Lomerizine Reversible cerebral vasoconstriction syndrome |
| Title | A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus |
| URI | https://dx.doi.org/10.1016/j.ensci.2021.100351 https://www.proquest.com/docview/2551578815 https://pubmed.ncbi.nlm.nih.gov/PMC8253938 https://doaj.org/article/645f45665ac64722a8d89e39583a83ef |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2405-6502 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001562612 issn: 2405-6502 databaseCode: KQ8 dateStart: 20150301 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals (WRLC) customDbUrl: eissn: 2405-6502 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001562612 issn: 2405-6502 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2405-6502 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001562612 issn: 2405-6502 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 2405-6502 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001562612 issn: 2405-6502 databaseCode: AKRWK dateStart: 20150301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central (WRLC) customDbUrl: eissn: 2405-6502 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001562612 issn: 2405-6502 databaseCode: RPM dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9ZAEF6kJy-iVPH1o6zg0WA2-5HssYqlCHqy0NuynzQSkpekKfQ_-KOdyUdJLvXiIZfNJtnMzGaeyc4-Q8jHKo_gmHORxaJ0mSijyBwGKyVgayeE5WmqQ_bjp7q8Et-v5fWm1BfmhM30wLPgPishEzh5Ja1HpvPCVqHSkWtZcVvxmPDrC25sE0wt-4ORGwsrywEiyQCGFCvl0JTcBSGiryE6LBimCXDJdm5pYu_feacN-tznTm6c0cVz8mxBkfR8Hv0L8iS2p-TPOfXgk2iXKPIy9WDsTaQ-9rg23NA7C4pANNjX014GupIVULuoKAaKv2UpCLvOjjfdAEdTH-swtbgu3G-uaQOdWaBrT5vxOA409vczBWw3jMNLcnXx7dfXy2wptpB5WZQsC0hEXwWmY-6QMMZHBcFYUJhVwqxmrlQ6MmUhwuEFUzppIXxVipDKXFc-8FfkpO3a-JpQblPwNnfJqyhSEtrFkhcw8Z0vuJXyQIpV1sYvTORYEKMxa8rZbzMpyKCCzKygA_n0cNFxJuJ4vPsXVOJDV2TRnhrAtsxiW-ZftnUgajUBswCSGWjArerHn_5hNRgD0xXXYGwbu3EwEMExiRT-IIVyZ0m7oe7PtPXNRPwN0TzXvHrzP97tLXmKA57T5d6Rk9t-jO8BX926s2kq_QVt8SWY |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+case+of+reversible+cerebral+vasoconstriction+syndrome+associated+with+anti-phospholipid+antibody+syndrome+and+systemic+lupus+erythematosus&rft.jtitle=eNeurologicalSci&rft.au=Atsushi+Shima&rft.au=Takakuni+Maki&rft.au=Naoya+Mimura&rft.au=Hirofumi+Yamashita&rft.date=2021-09-01&rft.pub=Elsevier&rft.issn=2405-6502&rft.eissn=2405-6502&rft.volume=24&rft.spage=100351&rft_id=info:doi/10.1016%2Fj.ensci.2021.100351&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_645f45665ac64722a8d89e39583a83ef |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-6502&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-6502&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-6502&client=summon |